Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CMA1 | P23946 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL144486 | 0.83 | ALDH1A1 (0.38) | CYP2A6SMN1; SMN2NPSR1LOXL2IDO1 | |
| SCHEMBL144441 | 0.77 | CYP2A6 (0.57) | CYP2A6SMN1; SMN2ALDH1A1CYP1A2CHRNA7 | |
| SCHEMBL5336284 | 0.77 | CYP2A6 (0.41) | CYP2A6SMN1; SMN2NPSR1LOXL2IDO1 | |
| SCHEMBL18003152 | 0.76 | CYP2A6 (0.39) | CYP2A6SMN1; SMN2NPSR1LOXL2IDO1 | |
| SCHEMBL17342267 | 0.75 | SMN1; SMN2 (0.40) | CYP2A6SMN1; SMN2NPSR1LOXL2IDO1 | |
| SCHEMBL12430 | 0.74 | TUBB4A (0.42) | CYP2A6NPSR1KDM4EALDH1A1CYP1A2 | |
| SCHEMBL9389492 | 0.74 | SMN1; SMN2 (0.46) | CYP2A6SMN1; SMN2KDM4EALDH1A1GAA | |
| SCHEMBL8291879 | 0.74 | CYP2A6 (0.36) | CYP2A6ALDH1A1 | |
| SCHEMBL28353826 | 0.74 | HSD17B10 (0.38) | CYP2A6SMN1; SMN2NPSR1LOXL2IDO1 | |
| SCHEMBL2092742 | 0.74 | CYP2A6 (0.38) | CYP2A6SMN1; SMN2NPSR1LOXL2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110117264-B | Phenyl sulfone derivative and application thereof in medicines | 广东东阳光药业有限公司 | 2023-06-09 | — | — | CN | disclosed |
| US-11396505-B2 | Inhibitors of CaMKK2 and uses of same | NEW YORK UNIVERSITY (US) | 2022-07-26 | — | — | US | disclosed |
| US-11332462-B2 | Heteroaryl compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2022-05-17 | — | — | US | disclosed |
| US-11332462-B2 | Heteroaryl compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2022-05-17 | — | — | US | disclosed |
| EP-3027615-B1 | ANTI-INFECTIVE COMPOUNDS | PASTEUR INSTITUT KOREA (KR) | 2021-07-21 | — | — | EP | disclosed |
| EP-3251679-B1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-12-16 | — | — | EP | disclosed |
| US-20200369656-A1 | INHIBITORS OF CAMKK2 AND USES OF SAME | NEW YORK UNIVERSITY | 2020-11-26 | — | — | US | disclosed |
| EP-2896397-B2 | Novel compounds having inhibitory activity against sodium-dependant glucose transporter | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-10-07 | — | — | EP | disclosed |
| US-20200277286-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2020-09-03 | — | — | US | disclosed |
| US-20200277286-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2020-09-03 | — | — | US | disclosed |
| EP-1266897-A2 | Hypoglycemic imidazoline compounds | ELI LILLY AND COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| EP-1228066-A2 | SULFONAMIDE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2002-08-07 | — | — | EP | disclosed |
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | ABBVIE INC. | 2002-07-04 | — | — | US | disclosed |
| US-6410562-B1 | ANTIDIABETIC AGENTS | ELI LILLY AND COMPANY | 2002-06-25 | — | — | US | disclosed |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2002-05-09 | — | — | US | disclosed |
| WO-2002024636-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2002-03-28 | — | — | WO | disclosed |
| WO-2001032646-A2 | SULFONAMIDE DERIVATIVES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-10 | — | — | WO | disclosed |
| WO-1999032112-A1 | METHOD FOR TREATING DIABETES | ELI LILLY AND COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999032482-A1 | HYPOGLYCEMIC IMIDAZOLINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
| EP-0924209-A1 | Hypoglycemic imidazoline compounds | ELI LILLY AND COMPANY (US) | 1999-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | CYP2A6 1825/4885SMN1; SMN2 1440/4885NPSR1 2840/4885 |
| US-11396505-B2 | Inhibitors of CaMKK2 and uses of same | CAMKK2, CAMKK1, CAMK1 | CYP2A6 4059/4885SMN1; SMN2 1047/4885NPSR1 4633/4885 |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | CYP2A6 2122/4885SMN1; SMN2 1656/4885NPSR1 3282/4885 |
| US-20200277286-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GRIN2C, TPMT | CYP2A6 118/4885SMN1; SMN2 1690/4885NPSR1 446/4885 |
| US-11332462-B2 | Heteroaryl compounds and methods of use thereof | COMT, GRIN2C, TPMT | CYP2A6 118/4885SMN1; SMN2 1690/4885NPSR1 446/4885 |
| US-20200369656-A1 | INHIBITORS OF CAMKK2 AND USES OF SAME | CAMKK2, CAMKK1, CAMK1 | CYP2A6 4059/4885SMN1; SMN2 1047/4885NPSR1 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.